STAT

Opinion: As a doctor, I was opposed to supervised injection facilities. Now I’m ready to give them a try

Despite the clear need to battle the opioid epidemic with all of the tools at our disposal, one evidence-proven option — supervised injection facilities — is being overlooked, and even…
A client of the Insite supervised injection Center in Vancouver, Canada, collects her kit in May 2011.

Over the last few years, I have watched with a blend of amazement and grave concern as an odd phenomenon has unfolded against the backdrop of our nation’s opioid crisis: Despite the clear need to battle this ongoing epidemic with all of the tools at our disposal, one evidence-proven option — supervised injection facilities — is being overlooked, and even disparaged.

Back in the spring, the Massachusetts Medical Society began advocating for the establishment of a pilot supervised injection facility in the commonwealth of Massachusetts. It was not

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Plans For Generic Wegovy, Cough Syrup Warnings, And More
Biocon is developing a generic version of Novo Nordisk's Wegovy and is prepared to conduct a clinical trial next year if needed.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.

Related Books & Audiobooks